Author:
Xibille Daniel,Carrillo Sandra,Huerta-Sil Gabriela,Hernández Ramiro,Limón Leonardo,Olvera-Soto Guadalupe,Jara-Quezada Luis Javier,Esquivel Abdieel,Pérez-Rodríguez Marcela
Reference52 articles.
1. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase iii trial;Maini;Lancet,1999
2. On the regulatory approval pathway of biosimilar products;Wang;Pharmaceuticals (Basel),2012
3. Biosimilars in rheumatology: current perspectives and lessons learnt;Dörner;Nat Rev Rheumatol,2015
4. The economics of biosimilars;Blackstone;Am Health Drug Benefits,2013
5. Norma Oficial Mexicana NOM-257-SSA1-2014, en materia de medicamentos biotecnológicos. Diario Oficial de la Federación, 11-12-2014. Available from: http://dof.gob.mx/nota_detalle.php?codigo=5375517&fecha=11/12/2014 [accessed 13.12.16]